Karyopharm announces preliminary unaudited 2023 revenue and 2024 objectives

– accelerating innovation and growth strategy with top-line data readouts expected in 2h 2024 and 2025 from three pivotal phase 3 studies evaluating selinexor in multiple myeloma, endometrial cancer and myelofibrosis –  – preliminary unaudited full year 2023 total revenue and u.s. xpovio® (selinexor) net product revenue expected to be approximately $146 million and $112 million, respectively, meeting company's guidance – – potential for selinexor to be a novel maintenance treatment for patients with tp53 wild-type endometrial cancer further strengthened with long-term exploratory subgroup analyses from siendo study; recruitment ongoing in the company's pivotal phase 3 study; further updates planned to be presented in 2024 – – opportunity to define a new myelofibrosis treatment paradigm based on the encouraging data presented from the phase 1 study of selinexor in combination with ruxolitinib in patients with treatment-naÏve myelofibrosis; recruitment ongoing in the company's pivotal phase 3 study; further updates planned to be presented in 2024 – – expect cash runway into late 2025 supporting company through multiple potentially value generating milestones – newton, mass. , jan. 8, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2023 total revenue and u.s. xpovio net product revenue estimates and outlined its 2023 achievements and 2024 objectives.
KPTI Ratings Summary
KPTI Quant Ranking